Heron Therapeutics announces FDA approval of Zynrelef for the management of postoperative pain for up to 72 hours.
Merck Inc. announces phase III KEYNOTE-522 trial met dual primary endpoint of event-free survival (EFS) in patients with high-risk early-stage triple-negative breast cancer.
Allergan/AbbVie acquires Soliton and with it Resonic a rapid acoustic pulse device for treatment of tattoo removal and cellulite
Merck KGaA out-licenses M 1095 to MoonLake Immunotherapeutics AG., a proposed treatment for psoriasis.
Minerva Neurosciences announces the results of the phase III trial of roluperidone for the treatment of negative symptoms of schizophrenia following completion of the 40-week open-label extension.
Phase III trial of Libtayo shows benefits in efficacy in cervical cancer.- Regeneron Pharma
Efficacy 0f Repatha across high-risk patient populations reinforced at ACC.21
Biogen exercises option to acquire TMS 007 for acute ischemic stroke based on positive phase IIa data.
DEBUT trial of Buvidal opioid dependence treatment is published in JAMA Open Network.- Camurus AB
INOVIO announces positive data from phase II segment of clinical trial evaluating INO-4800, its COVID-19 DNA Vaccine.
FDA expands approval of Comirnaty for young people with COVID-19.- Pfizer and BioNTech
Tezepelumab BLA is submitted to the FDA to treat severe asthma. Amgen + AstraZeneca
FDA approval of Ferriprox for treatment of transfusional iron overload due to sickle cell disease.- Chiesi Global Rare Diseases.
European Commission grants extended approval for Xtandi to treat metastatic castration-sensitive prostate cancer.- Astellas.
Tecentriq approved by European Commission as a first-line monotherapy treatment for people with a type of metastatic NSCLC.- Roche
Phase III FIGARO-DKD study of BAY 94 8862 meets primary endpoint in patients with chronic kidney disease and type 2 diabetes.- Bayer HealthCare
Aurinia announces publication of AURORA 1 phase III study results with Lupkynis for the treatment of lupus nephritis in The Lancet.
Cassava Sciences announces initiation of simufilam in patients with Alzheimer’s disease in a
phase III cognition maintenance study.
Athenex acquires Kuur Therapeutics Inc.
Use of the AstraZeneca COVID-19 (AZD1222) vaccine: updated Joint Committee on Vaccination and Immunisation (UK) statement.
Auris Medical provides update on Bentrio program in allergy.
Broad efficacy and improved safety profile of HyBryte presented at Society for Investigative Dermatology Virtual Meeting.- Soligenix Inc.
Positive results from GENESIS Phase III trial of motixafortide in stem-cell mobilization for autologous bone marrow transplantation in multiple myeloma .BioLineRx Ltd
Imfinzi + tremelimumab + chemotherapy demonstrated overall survival benefit in POSEIDON trial for 1st-line stage IV non-small cell lung cancer.- AstraZeneca
FDA advisory committee votes on recommending CCX 168 for approval in vasculitis.- ChemoCentryx
Phase III ORARIALS-01 trial of arimoclomol fails to meet endpoints in amyotrophic lateral sclerosis.- Orphazyme
China National Medical Products Administration grants conditional approval for pamiparib to treat gBRCA ovarian cancer.- BeiGene
Clinical value beyond price alone: biosimilars improve patient access to treatment
Long-term topical management of psoriasis: the road ahead
Over the horizon: early stage trials for NASH
Phase II trials and stem cell therapies
The next global epidemic
The latest treatments in NASH
The future of organ transplantation
Complications of stem cell transplants
Treating rejection in organ transplants
Challenges in transplant organ rejection
Biologic efficacy for complications associated with moderate-to-severe psoriasis
Moderate-to-severe psoriasis: treatment for young women
Migraine treatments: On the horizon
An independent review of current treatments for migraine
Migraine: The forgotten epidemic?
NEW: Moderate to Severe Asthma Learning Zone launches on Medthority.com
Senolytics: Can we treat age-related diseases with a single drug